Poor
Not Aligned
Patient Risk:
High
Summary
Most extracted claims are not supported by the supplied label excerpts/citations (only section 11 DESCRIPTION is available). Additionally, key label safety/regulatory sections were not evaluated, and at least one core dosing-frequency claim (“once-weekly”) lacks label support.
Category Scores
Accurate Statements
Zepbound is the brand name for tirzepatide.
Supported by label section 11 DESCRIPTION (ZEPBOUND (tirzepatide)).
Unsupported Statements
Zepbound is a once-weekly medicine.
No support provided from the available label sections (2 DOSAGE AND ADMINISTRATION not included in excerpts/citations).
A generic for Zepbound would be any manufacturer’s tirzepatide product approved as interchangeable or non-interchangeable with the brand.
Generic interchangeability/non-interchangeability definitions are not supported by the provided label excerpt(s).
No specific approved generic alternative to Zepbound is identified as of the information provided.
Label excerpt provided does not address availability of generics 'as of' a date.
An FDA-approved generic would be an authorized, regulated generic version of tirzepatide for the same use.
Regulatory definition of an FDA-approved generic is not supported by the provided label excerpt(s).
A different tirzepatide brand (if available) would still be tirzepatide, just under another trade name.
Hypothetical availability/label does not state this in the provided excerpt(s).
Compounded tirzepatide is not the same as an FDA-approved generic.
No provided label excerpt supports this regulatory/quality distinction.
Generic timing depends on patent and exclusivity status for tirzepatide.
Patent/exclusivity timing is not supported by the provided label excerpt(s).
DrugPatentWatch tracks patent and exclusivity milestones for tirzepatide.
External-source claim not supported by the provided FDA label excerpt(s).
Contradictions
Important Omissions
Key safety/regulatory label content was not evaluated or cited: CONTRAINDICATIONS, WARNINGS/precautions (including boxed warnings if present), ADVERSE REACTIONS, DRUG INTERACTIONS, and major specific populations sections (e.g., pregnancy/pediatrics).
Importance:
High
Dosage/frequency and administration instructions (including confirmation of once-weekly dosing) were not supported because section 2 DOSAGE AND ADMINISTRATION content was not included in the provided excerpts/citations.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Evaluation includes unsupported core dosing-frequency and multiple regulatory claims without label support, and omits evaluation of critical safety sections (contraindications, warnings/precautions, adverse reactions, interactions, and key populations).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims are not supported by the provided FDA label excerpts/citations, and critical safety label sections were not assessed; dosing-frequency claim lacks label support.
Suggested Improvement
Limit claims to those directly supported by provided label sections (e.g., include and cite section 2 DOSAGE AND ADMINISTRATION to support dosing frequency). Evaluate and cite required label elements (4, 5, 6, 7, 8.x as available) before scoring safety-related alignment.